<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol dependence</journal-title></journal-title-group><issn pub-type="ppub">0376-8716</issn><issn pub-type="epub">1879-0046</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12045330</article-id><article-id pub-id-type="pmcid-ver">PMC12045330.1</article-id><article-id pub-id-type="pmcaid">12045330</article-id><article-id pub-id-type="pmcaiid">12045330</article-id><article-id pub-id-type="manuscript-id">NIHMS2073478</article-id><article-id pub-id-type="pmid">39159600</article-id><article-id pub-id-type="doi">10.1016/j.drugalcdep.2024.112410</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2073478</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2073478</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Cascade of Care for Commercially Insured Persons with Opioid Use Disorder and Comorbid HIV and HCV Infections</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ivasiy</surname><given-names initials="R">Roman</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Madden</surname><given-names initials="LM">Lynn M.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>DiDomizio</surname><given-names initials="E">Elizabeth</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Johnson</surname><given-names initials="KA">Kimberly A.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Machavariani</surname><given-names initials="E">Eteri</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahmad</surname><given-names initials="B">Bachar</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oliveros</surname><given-names initials="D">David</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ram</surname><given-names initials="A">A</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kil</surname><given-names initials="N">Natalie</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Altice</surname><given-names initials="FL">Frederick L.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref></contrib></contrib-group><aff id="A1"><label>1</label>Yale School of Medicine, Section of Infectious Diseases, New Haven, CT, United States</aff><aff id="A2"><label>2</label>APT Foundation, New Haven, CT, United States</aff><aff id="A3"><label>3</label>College of Behavioral and Community Science, Department of Mental Health Law and Policy, University of South Florida, Tampa, FL, USA</aff><aff id="A4"><label>4</label>Yale School of Medicine, New Haven, CT, United States</aff><aff id="A5"><label>5</label>Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States</aff><aff id="A6"><label>6</label>Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut, USA</aff><aff id="A7"><label>7</label>Yale School of Public Health, Department of Epidemiology of Microbial Diseases, New Haven, CT, United States</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">2. Author Contributions</p><p id="P2">RI: conceptualization, methodology, and writing&#8212;original draft. LMM: conceptualization, methodology. ED: data curation and collection, research management. KAJ: conceptualization and methodology. EM and BA: conceptualization, data curation, and methodology. DO: review editing. AR: methodology. NK: Supervision. FLA: conceptualization, methodology, writing&#8212;original draft, and writing&#8212;review editing. All authors contributed to the article and approved the submitted version.</p></fn><corresp id="CR1"><underline>Contact</underline>: Frederick L. Altice, M.D., <underline>Address</underline>: 135 College Street, Suite 323, New Haven, CT 06510-2283, <email>Frederick.Altice@yale.edu</email>, <underline>Fax</underline>: +1.203.737.4051</corresp><fn fn-type="COI-statement" id="FN5"><p id="P36"><underline>Declarations of Interest:</underline> None</p></fn><fn fn-type="COI-statement" id="FN6"><p id="P37">Conflict of Interest Statement</p><p id="P38">The authors report no declarations of interest.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>12</day><month>8</month><year>2024</year></pub-date><volume>263</volume><issue-id pub-id-type="pmc-issue-id">487698</issue-id><fpage>112410</fpage><lpage>112410</lpage><pub-history><event event-type="nihms-submitted"><date><day>27</day><month>04</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-02 10:26:07.953"><day>02</day><month>05</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2073478.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P3">Opioid use disorder (OUD) significantly impacts individual and public health and exacerbated further by concurrent infectious diseases. A syndemic approach is needed to address the intertwined OUD, HIV and HCV epidemics, including expanded use of medications for opioid use disorder (MOUD).</p></sec><sec id="S2"><title>Methods:</title><p id="P4">To identify MOUD scale-up opportunities, we conducted retrospective cohort study, representing commercially insured persons, created the OUD care continuum, including HIV and HCV influences in adults (18&#8211;64 years) newly diagnosed with OUD in 2019 using Merative MarketSan data.</p></sec><sec id="S3"><title>Results:</title><p id="P5">Among 124,467,633 individuals, the prevalence of OUD was 0.4% (95% CI: 0.36%&#8211;0.46%; N = 497,871), with 327,277 (65.7%, 95% CI: 65.60%&#8211;65.87%) newly diagnosed in 2019. Among these newly diagnosed individuals (34% men, mean age 44&#177;0.01), 53,568 (27.0%, 95% CI: 26.4%&#8211;27.5%) were prescribed MOUD, with retention rates at 1, 3, and 6 months being 89.0% (95% CI: 88.2%&#8211;89.8%), 66.0% (95% CI: 64.8%&#8211;67.2%), and 50.3% (95% CI: 48.3%&#8211;51.6%), respectively. Buprenorphine was the most prescribed MOUD (79.6%, 95% CI: 78.6%&#8211;80.7%), followed by XR-NTX (14.9%, 95% CI:14.0%&#8211;15.8%) and methadone (5.5%, 95% CI: 4.9%&#8211;6.1%). Six-month retention was highest for methadone (73.4%, 95% CI: 73.0%&#8211;73.8%), however, followed by buprenorphine (55.7%, 95% CI: 55.3%&#8211;57.1%) and substantially lower for XR-NTX (12.6%, 95% CI: 10.6%&#8211;14.6%). Screening for HIV and HCV was low among OUD enrollees (11.1%, 14.4%), slightly higher for MOUD initiators (18.0%, 21.6%). Being prescribed MOUD was correlated with HCV infection (AOR: 2.54; 95% CI: 2.41&#8211;2.68), HCV/HIV coinfection (AOR: 1.89; 95% CI: 1.41&#8211;2.53), and hospitalization for OUD-related services (AOR: 1.14; 95% CI: 1.11&#8211;1.17), yet hospitalization for OUD-related services was positively correlated with XR-NTX (AOR: 2.72; 95% CI: 2.56&#8211;2.85) prescription and negatively with methadone (AOR: 0.19; 95% CI: 0.16&#8211;0.23) prescription. Having HIV was negatively correlated with being prescribed methadone (AOR: 0.33; 95% CI: 0.13&#8211;0.86).</p></sec><sec id="S4"><title>Conclusions:</title><p id="P6">Substantial gaps in the OUD cascade persist, underscoring better implementation opportunities for MOUD prescription in hospital-based settings and expanding access to methadone beyond highly regulated sites given its low coverage yet high treatment retention.</p></sec></abstract><kwd-group><kwd>Opioid use disorder</kwd><kwd>cascade of care</kwd><kwd>medications for opioid use disorder (MOUD)</kwd><kwd>communicable comorbidities</kwd><kwd>HIV</kwd><kwd>HCV</kwd><kwd>treatment initiation</kwd><kwd>treatment retention</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>